Bpifrance

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Laurent Arthaud

Managing Director

Marion Aubry

Investment Director

Emmanuel Audouard

Director of Transverse Venture Capital Investments Division

Benoit Barteau Ph.D

Investment Director

Nicolas Berdou

Investment Director, Defense Expert

Jérémy Berthuin

Health Sector Manager

Clarisse Blandin

Investment Director

Elyssa Maufras du Châtellier

Investment Director

Edouard Combette

Investment Director

Charlotte Corbaz

Deputy Director of the Large Venture Fund and Deputy Managing Director

Nicolas Dardenne

Senior Investment Director, Normandy (Caen Rouen)

Arnaud Despoisse

Director of Occitanie Participations

Philippe Dutheil

Investment Director

Mailys Ferrere

Director of Large Venture Investments

Paul-Francois Fournier

Executive Director, Innovation Department

Pierre Gillet

Investment Director

Vanessa Giraud

Managing Director

Gwenaël Hamon

Senior Investment Director

Laurent Higueret Ph.D

Senior Investment Director

Louis Janneau

Investment Director and Fund Manager

Magali Joessel

Director of Funds

So-Yeon Koo

Senior Investment Manager

Jérôme Langlade

Investment Director Aquitaine / Limousin / Poitou-Charentes

Eric Lefebvre

Director

Stephane Lefevre-Sauli

Senior Investment Director

Arnaud Legardeur

Investment Director

Chahra Louafi

Senior Investment Director

Quentin Mayolle

Senior Investment Officer

Serge Mesguich

Director of FIT

Laure Michel

Investment Director

Louis Molis

Investment Director

Jean-Francois Morin

Investment Director

Sébastien Moynot

Director

Adrien Muller

Investment Director

Adrien Néel

Investment Director

François Picarle

Executive

Axel Piriou

Director of Investments

Olivier Rameil

Senior Investment Director / VC seed

Vincent Roque

Director

Thibaut Roulon Ph.D

Investment Director

Gilles Schang

Deputy Director

Alban Stamm

Innovation Delegate

Pierre-Alain Truan

Innovation Delegate

Claire Waché

Senior Investment Officer

Pascale Courcelle

Director of Real Estate Financing, Energy Environment

Jean-Marie Fougeray

Senior Investment Director, Brittany

Past deals in Lyon

Objow

Seed Round in 2024
Objow is a gamified application designed to stimulate employee involvement in achieving goals. The platform centralizes employee performance data to set personalized goals, motivate and coach teams daily, and convert performance points into rewards, enabling businesses to increase employee engagement and productivity. By aligning individual efforts with organizational objectives, Objow supports ongoing motivation and performance improvement. The solution is part of a France-based technology offering established in 2018 in Lyon that focuses on internet-based tools to enhance sales team performance.

MaaT Pharma

Post in 2024
MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Langa International

Venture Round in 2024
Langa International is an independent energy producer based in Lyon, France, specializing in the development, construction, and operation of renewable energy facilities. The company focuses on a diverse range of renewable energy solutions, including solar, wind, hydroelectricity, energy storage, and green hydrogen. By imagining, designing, and deploying innovative and competitive energy solutions, Langa International enables the realization of projects worldwide, contributing to the global transition towards sustainable energy sources.

B2ebike

Venture Round in 2023
B2ebike is a Lyon, France-based manufacturer of electric bikes, offering models such as the B2 city range and B2 boost range. The company provides comprehensive electric bicycle fleet solutions for businesses and communities to promote electric mobility. It also develops a sustainable mobility platform that enhances performance and well-being and offers mobility plans to real estate developers, including hotels and peri-urban industrial sites, enabling clients to adopt electrically assisted bicycles through dedicated terminals and applications.

Mon Petit Placement

Venture Round in 2023
Mon Petit Placement, SAS is a company based in Lyon, France, founded in 2017, that specializes in developing an online financial platform aimed at enhancing young people's saving habits. The platform serves as an intermediary between portfolio management companies and banking institutions, providing users with a personalized investment strategy. It is designed to be user-friendly and engaging, allowing young investors to make informed investment decisions while cultivating better savings practices. Through its innovative approach, Mon Petit Placement seeks to empower the next generation of investors by simplifying the investment process and promoting financial literacy.

Rushmix

Venture Round in 2021
Rushmix SAS is a video editing company based in Lyon, France, founded in 2018. It operates a platform that allows users to transform their photos and videos into polished short films within 72 hours. The service caters to a variety of needs, offering products such as sports films, wedding films, family movies, travel videos, and custom films. By simplifying the video creation process, Rushmix aims to enhance digital communication for both consumers and businesses, enabling them to effectively convey their messages through engaging visual content.

1Kubator

Venture Round in 2021
1Kubator is an innovation network that supports start-up companies through various initiatives aimed at fostering entrepreneurship. The company provides training, incubation programs, acceleration programs, and open innovation offerings across several French cities, including Lyon, Bordeaux, Nantes, Rennes, Lille, and Strasbourg. By focusing on empowering young entrepreneurs, 1Kubator aims to facilitate the growth and development of start-ups, helping them achieve their potential in a competitive market.

B-Hive Engineering

Venture Round in 2020
B-Hive Engineering is an engineering and operational consulting company based in Mulhouse, France, with additional operations in Lyon, Paris, and Montréal, Canada. Founded in 2017, the company specializes in providing technical assistance and project management services across various sectors, including chemistry, petrochemistry, energy, food, pharmaceuticals, biotechnology, automotive, rail, aeronautics, and civil engineering. B-Hive Engineering focuses on delivering support throughout the study and design phases of projects, ensuring efficient solutions to clients' operational challenges. By offering expertise in urban planning, structural engineering, and infrastructure development, the company plays a crucial role in facilitating advancements in industry, transportation, and construction.

Fab'entech

Series C in 2020
Fab’entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂], targeting emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech aims to provide healthcare institutions with effective treatments for urgent medical situations. As a member of the LyonBiopôle cluster, the company is positioned within a vibrant network dedicated to advancing biopharmaceutical innovation.

Laclarée

Seed Round in 2019
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

FinKey

Seed Round in 2019
FinKey is a financing advisory firm established in 2017 and headquartered in Lyon, France. It specializes in mergers and acquisitions, offering strategic advisory services to small and medium-sized businesses. The firm assists these companies in identifying suitable investment banks and investors, focusing particularly on sectors such as information technology, software, cloud technology, and software as a service (SaaS). By leveraging its expertise, FinKey aims to facilitate successful transactions and support the growth of its clients.

ADDEV Materials

Private Equity Round in 2019
Founded in 2006, ADDEV Materials specializes in the manufacturing and distribution of high-performance materials. Its product portfolio includes adhesive tapes, glues, mastics, abrasives, personal protection equipment, insulation systems, components, and resins. The company caters to various industries such as automotive, aerospace, energy, railway, nuclear, and medical.

ENYO Pharma

Series B in 2018
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Fill Up Média

Venture Round in 2017
Fill Up Média is a French advertising agency that specializes in installing advertising screens at fuel dispensing pumps. Founded in 2011 and based in Lyon, the company offers a unique communication medium that enables the display of multimedia advertising content during the fueling process. With a network of approximately 4,400 screens across more than 630 gas stations in France, Fill Up Média serves as a significant player in external communication within the industry. The screens provide a platform for targeted and engaging advertising, enriching the customer experience while they refuel.

Wizaplace

Venture Round in 2016
Founded in 2012, Wizaplace is a French software company that provides an all-in-one SaaS platform for creating and managing marketplaces. Its solution integrates essential functions for building and operating B2C, B2B, C2C, and tailor-made service marketplaces, along with e-commerce, crowdfunding, and collaborative platforms.

Poxel

Series B in 2014
Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.